Resource Center
FOR PHARMCEUTICAL MANUFACTURERS
Understanding Prescription Drug Line Extensions: Key Insights on URA, Medicaid Rebates, and 340B Program Impact
For pharmaceutical manufacturers acquiring or launching brand drugs, line extensions remain a topic fraught with frequent inquiries and complexities. Line extensions, with their unique formulas to determine the Unit Rebate Amount (URA), can often be a source of...
Navigating Change: A Deep Dive into the Pending CMS Rule (CMS-2434) for Pharma Manufacturers
Navigating Change: A Deep Dive into the Pending CMS Rule (CMS-2434) for Pharma Manufacturers The CMS Final Rule currently pending holds significant implications for pharmaceutical manufacturers. Within the Office of Information and Regulatory Affairs (OIRA), there are...
Navigating the Texas Medicaid Formulary: A Comprehensive Guide for Pharmaceutical Manufacturers
NAVIGATING THE TEXAS MEDICAID FORMULARY: A Comprehensive Guide for Pharmaceutical ManufacturersThe landscape of pharmaceutical product listing in Texas presents unique challenges for manufacturers seeking Medicaid coverage. Unlike other states, Texas operates its own...
Overview of the 2025 Medicare Part D Program Redesign: A Paradigm Shift for Pharma Manufacturers
Overview of the 2025 Medicare Part D Program Redesign: A Paradigm Shift for Pharma Manufacturers The Medicare Modernization Act of 2003 included the Coverage Gap or Donut Hole, as it’s commonly referred to, as a part of the redesign of the Part D drug benefit. This...
Navigating the Changing Landscape of Pharmaceutical State Price Transparency Reporting
Navigating the Changing Landscape of Pharmaceutical State Price Transparency Reporting In the world of pharmaceutical manufacturing, staying up to date on regulatory changes and market dynamics is essential for success. Recently, there has been a significant shift...
The 2024 Medicaid AMP Cap Removal: What Pharma Manufacturers Need to Know
2024 AMP CAP REMOVAL What You Need To Know2024 AMP CAP REMOVAL – WHAT PHARMA MANUFACTURERS NEED TO KNOWThe 2024 Medicaid AMP cap removal will be effective January 1st, 2024, and may have sweeping impacts for drug manufacturers participating in the Medicaid program....
Medicaid – From a Simple Concept to an Operational Labyrinth
Medicaid – From a Simple Concept to an Operational LabyrinthThe federal government created Medicaid in 1965 as a public insurance program to expand existing federal support for healthcare services. It has since ballooned from its basic insurance program roots. Today,...
Key Terms in Pharmaceutical Government Pricing
Key Terms in Pharmaceutical Government PricingPharmaceutical pricing can be a challenge to understand and a difficult landscape to navigate. There are multiple prices set for each individual National Drug Code (NDC) – some publicly available and some not. WAC, ASP,...
Understanding Class of Trade (COT) in the Pharmaceutical Industry
For pharmaceutical manufacturers, assigning Class of Trade designations to government pricing data can be a tedious exercise. However, it can have large implications on Medicaid rebate liabilities and present compliance risks if not managed correctly. Let’s take a...
Professor Jeremy’s
KEY TERMS
FOR PHARMA EXECUTIVES
Pharmaceutical professionals often face challenges with the industry’s language, acronyms, and key players. This glossary offers an overview of essential terms every executive should know.